CDMO - ペレグリン・ファ―マシュ―ティカルズ (Avid Bioservices Inc.) ペレグリン・ファ―マシュ―ティカルズ

 CDMOのチャート


 CDMOの企業情報

symbol CDMO
会社名 Avid Bioservices Inc (ペレグリン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アビッド・バイオサービシズ(Avid Bioservices Inc.)(旧名:Peregrine Pharmaceuticals Inc.)は、癌の治療・診断用モノクローナル抗体を開発するバイオ医薬品会社。同社の治験モノクローナル抗体のパイプラインはホスファチジルセリン(PS)を標的とする抗体、及びデオキシリボ核酸(DNA)・ヒストン標的とする抗体を含む2つの技術プラットフォームに基づく。「Bavituximab」は同社のPSを標的とする抗体である。「Bavituximab」は治療可能性を明示し、癌の治療に対する新しい方法を示す。「PGN650」はPSを標的とする造影剤であり、癌造影の新しい方法が望まれる。同社は第一・第二選択非小細胞肺がんと第一選択膵臓がんのための標準的化学療法と組み合わせる「Bavituximab」の3つのランダム化第II相試験を実行している。同社は「Bavituximab」に関する会社提供の試験の他、異なる併用療法と腫瘍適応に関する治験責任医師提供の試験4つを有している。  ペレグリン・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。ホスファチジルセリンを標的とする技術プラットフォ―ムに基づき、癌の治療および診断に焦点を当て、臨床試験における薬剤候補を研究、開発する。同社の鍵となる免疫療法候補、バビツキシマブ(bavituximab)は、非小細胞肺癌などの治療のために開発中である。   
本社所在地 2642 Michelle Drive Suite 200 Tustin CA 92780 USA
代表者氏名 Roger J. Lias ロジャー・リアス
代表者役職名 President Chief Executive Officer
電話番号 +1 714-508-6100
設立年月日 29738
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 186人
url www.peregrineinc.com
nasdaq_url https://www.nasdaq.com/symbol/cdmo
adr_tso
EBITDA EBITDA(百万ドル) -21.61700
終値(lastsale) 5.74
時価総額(marketcap) 321448357.44
時価総額 時価総額(百万ドル) 312.48810
売上高 売上高(百万ドル) 39.13300
企業価値(EV) 企業価値(EV)(百万ドル) 275.09910
当期純利益 当期純利益(百万ドル) -30.01000
決算概要 決算概要 BRIEF: For the three months ended 31 July 2018 Avid Bioservices Inc revenues decreased 54% to $12.6M. Net loss applicable to common stockholders excluding extraordinary items totaled $3.4M vs. income of $1.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Interest and other expense increase from $3K to $11K (expense).

 CDMOのテクニカル分析


 CDMOのニュース

   Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing  2021/02/03 12:00:00 Business Wire
BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune h
   Avid Bioservices Announces Closing of Public Offering of Common Stock  2020/12/14 21:05:00 GlobeNewswire
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and…
   Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors - Stocks News Feed  2020/12/07 21:05:00 Stocks News Feed
TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma as an independent member of the company’s board… Read More »Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
   Avid Bioservices, Inc. (CDMO) Q2 2021 Earnings Call Transcript  2020/12/03 01:11:02 AlphaStreet
Avid Bioservices, Inc. (NASDAQ: CDMO) Q2 2021 earnings call dated Dec. 02, 2020 Corporate Participants: Tim Brons — Investor Relations Nicholas Green — President and Chief Executive Officer Daniel Hart — Chief Financial Officer Timothy Compton — Chief […]
   Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | AlphaStreet  2020/09/02 03:36:25 AlphaStreet
Avid Bioservices, Inc. (NASDAQ: CDMO) Q1 2021 earnings call dated Sep. 01, 2020
   Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | AlphaStreet  2020/09/02 03:36:25 AlphaStreet
Avid Bioservices, Inc. (NASDAQ: CDMO) Q1 2021 earnings call dated Sep. 01, 2020
   Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | The Motley Fool  2020/09/01 22:30:14 The Motley Fool
CDMO earnings call for the period ending July 31, 2020.
   Global CDMO Market: Opportunities & Competitive Landscape 2020-2025 - ResearchAndMarkets.com  2020/08/31 16:19:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Market Opportunities and Competitive Landscape for CDMO" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the pharmaceutical industry and the role contract development and manufacturing organizations (CDMO) play in it. This analysis includes a review of the global CDMO market by-service type, drug molecule type, and end-use. This report limits the CDMO market landscape to the US and European regions and analyzes
   U.S. Army Contracting Command Awards Ology Bioservices Contract to Reserve Production Capacity in Support of Operation Warp Speed  2020/08/26 12:00:00 Business Wire
ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland. The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of award. In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and
   Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Highlights the Impact of COVID-19 (2020-2024) | Growing Pharmaceutical Industry to boost the Market Growth | Technavio  2020/08/14 16:00:00 Business Wire
LONDON--(BUSINESS WIRE)-- #ContractDevelopmentandManufacturingOrganizationCDMOOutsourcingMarket--The Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market will grow by USD 44.17 bn during 2020-2024
   Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | AlphaStreet  2020/09/02 03:36:25 AlphaStreet
Avid Bioservices, Inc. (NASDAQ: CDMO) Q1 2021 earnings call dated Sep. 01, 2020
   Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | The Motley Fool  2020/09/01 22:30:14 The Motley Fool
CDMO earnings call for the period ending July 31, 2020.
   Global CDMO Market: Opportunities & Competitive Landscape 2020-2025 - ResearchAndMarkets.com  2020/08/31 16:19:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Market Opportunities and Competitive Landscape for CDMO" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the pharmaceutical industry and the role contract development and manufacturing organizations (CDMO) play in it. This analysis includes a review of the global CDMO market by-service type, drug molecule type, and end-use. This report limits the CDMO market landscape to the US and European regions and analyzes
   U.S. Army Contracting Command Awards Ology Bioservices Contract to Reserve Production Capacity in Support of Operation Warp Speed  2020/08/26 12:00:00 Business Wire
ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland. The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of award. In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and
   Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Highlights the Impact of COVID-19 (2020-2024) | Growing Pharmaceutical Industry to boost the Market Growth | Technavio  2020/08/14 16:00:00 Business Wire
LONDON--(BUSINESS WIRE)-- #ContractDevelopmentandManufacturingOrganizationCDMOOutsourcingMarket--The Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market will grow by USD 44.17 bn during 2020-2024

 関連キーワード  (医薬品 米国株 ペレグリン・ファ―マシュ―ティカルズ CDMO Avid Bioservices Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)